MedTrace Logo

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

NCT00279422 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2012-03-12

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.

Conditions

Interventions

DRUG

visilizumab

DRUG

visilizumab

Sponsors & Collaborators

  • PDL BioPharma, Inc.

    collaborator INDUSTRY

  • Facet Biotech

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Canada
  • Czechia
  • France
  • Germany
  • Hungary
  • Israel
  • Netherlands
  • Norway
  • Slovakia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00279422 on ClinicalTrials.gov